On February 10, 2026, Solace Health announced a $130 million Series C funding round led by IVP, accelerating the company’s mission to make advocacy a standard part of care for every patient in the United States. The Series C values Solace at over $1 billion and reflects growing consensus that healthcare advocacy is no longer optional as costs rise and systems fracture. Wilson Sonsini Goodrich & Rosati advised IVP on the transaction.

The round also included participation from existing investors Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures. With this funding, Solace will significantly expand its national network of more than 2,000 experienced advocates serving Medicare and Medicare Advantage members, while accelerating investment in its platform and clinical research. The company will also deepen partnerships with payers and providers to embed advocacy earlier in the care journey where outcomes are most at risk.

The Wilson Sonsini team that advised IVP on the transaction included Becki DeGraw, Madeleine Vella, Andrea Linna, Nawa Lodin, Chris Paniewski, Isabel Annino, and Daniel Chen.

For more information, please see Solace Health’s news release. Additional coverage is available on Fierce Healthcare and MedCity News.